AGE AgeX Therapeutics

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00 p.m. ET.

A live webcast of the presentation can be accessed from the of Serina’s website, where an archived replay of the event will also be available for a limited time.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit .

For inquiries, please contact:



(256) 327-9630



EN
04/09/2024

Underlying

AGEAgeX Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AgeX Therapeutics

 PRESS RELEASE
Free
AGE AgeX Therapeuti...

Serina Therapeutics Reports Third Quarter 2024 Financial Results and P...

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights Partnership and Presentations with Enable Injections: Building...

November 12, 2024 1 EN
 PRESS RELEASE
Free
AGE AgeX Therapeuti...

Serina Therapeutics Makes Grants to New Employees Under Inducement Pla...

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 60,500 shares of Serina’s common stock to three new non-executive employees on November 6, 2024 (each, an “Option Grant”). Each Option Grant has an exercise...

November 11, 2024 1 EN
 PRESS RELEASE
Free
AGE AgeX Therapeuti...

Serina Therapeutics to Present at the 14th Annual Injectables Summit

Serina Therapeutics to Present at the 14th Annual Injectables Summit HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 14th Annual Injectables Summit in Boston, MA. The joint presentation, with Enable Injections’ Chief Commercial Officer Matthew Huddleston, is entitled “Patient-enabled Therapy for Advance...

October 2, 2024 1 EN
 PRESS RELEASE
Free
AGE AgeX Therapeuti...

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Glob...

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00 p.m. ET. A live webcast of the presentation can be accessed from the of Serina’s website, where an ...

September 4, 2024 1 EN
 PRESS RELEASE
Free
AGE AgeX Therapeuti...

Serina Therapeutics Reports Second Quarter 2024 Financial Results and ...

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) --  (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights. Recent Highlights  ●Partnership with Enable Injections. The Company will develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuseTM for the treatment of Parkinson’s disease. T...

August 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch